Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg-Reference-Cited by-同舟云学术

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg

Published:2013-09-26 Issue:13 Volume:122 Page:2185-2194
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Baur Andreas S.¹²,Lutz Manfred B.³,Schierer Stephan¹,Beltrame Luca⁴,Theiner Gabi¹,Zinser Elisabeth⁵,Ostalecki Christian¹,Heidkamp Gordon¹,Haendle Ina¹,Erdmann Michael¹,Wiesinger Manuel¹,Leisgang Waltraud¹,Gross Stefanie¹,Pommer Ansgar J.¹,Kämpgen Eckhart¹,Dudziak Diana¹,Steinkasserer Alexander⁵,Cavalieri Duccio⁶,Schuler-Thurner Beatrice¹,Schuler Gerold¹

Affiliation:

1. Department of Dermatology, University Hospital Erlangen, Erlangen, Germany;

2. Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL;

3. Institute of Virology and Immunobiology, University of Würzburg, Würzburg, Germany;

4. Translational Genomics Unit, Department of Oncology, “Mario Negri” Pharmacological Research Institute, Milano, Italy;

5. Department of Immune-Modulation, University Hospital Erlangen, Erlangen, Germany; and

6. Department of Pharmacology, University of Firenze, Firenze, Italy

Abstract

Key Points ONTAK blocks DC maturation by coreceptor downmodulation and inhibition of Stat3 phosphorylation to induce a tolerogenic phenotype. ONTAK kills activated CD4 T cells but stimulates antiapoptosis in resting Treg by engagement and stimulation through CD25.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/13/2185/1368153/2185.pdf

Reference48 articles.

1. Cancer immunotherapy via dendritic cells.;Palucka;Nat Rev Cancer,2012

2. Recent developments in cancer vaccines.;Palucka;J Immunol,2011

3. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.;Draube;PLoS ONE,2011

4. Regulatory T cells: overcoming suppression of T-cell immunity.;Golovina;Cancer J,2010

5. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.;Frankel;Cancer,2006

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T Cell Inhibition by P60 Combined with Adenoviral AFP Transduced Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma;Immunological Investigations;2023-10-17

2. Role of β-catenin in PD-L1 expression of nasopharyngeal carcinoma;Heliyon;2023-07

3. Antibody–drug conjugates come of age in oncology;Nature Reviews Drug Discovery;2023-06-12

4. Targeting breast cancer stem cells directly to treat refractory breast cancer;Frontiers in Oncology;2023-05-12

5. Harnessing the immune system in the treatment of cutaneous T cell lymphomas;Frontiers in Oncology;2023-01-12